Please read and agree to the
terms and conditions
of this site.
I agree
Medical Technology
/tech
Clear filters and search
Format
photo
Tags
biotech
9
×
boston blog main
boston top stories
boulder/denver blog main
boulder/denver top stories
detroit blog main
9
×
detroit top stories
fda
9
×
glaxosmithkline
9
×
life sciences
national
national blog main
national top stories
new york blog main
new york top stories
raleigh-durham blog main
raleigh-durham top stories
san diego blog main
san diego top stories
san francisco blog main
san francisco top stories
seattle blog main
seattle top stories
texas blog main
texas top stories
wisconsin blog main
wisconsin top stories
indiana blog main
indiana top stories
clinical trials
amgen
eli lilly
ipo
bristol-myers squibb
cancer
medical devices
novartis
scott gottlieb
startups
abbvie
What
roundup
bio
cancer
crispr
days
biotech
black
bucks
diamond’s
drugs
moves
news
therapeutics
week
abbvie’s
according
ahead
akcea
alliance
allogene
annual
appetite
ash
august
barcelona
big
biofourmis
bosley's
bosley’s
bread
bridge
bristol
busy
butter
buy
buyout
calls
cas
cases
cash
Language
unset
Current search:
fda
×
biotech
×
" detroit blog main "
×
glaxosmithkline
×
@xconomy.com
3 years ago
Bio Roundup: CRISPR Kudos, Bristol Myers’s Buy, RNAi Alliance & More
@xconomy.com
3 years ago
Bio Roundup: Pharma M&A, AbbVie’s Cancer Bet, Biofourmis Bucks & More
@xconomy.com
4 years ago
Bio Roundup: Mammoth Moves, Black Diamond’s Pop, Ohana’s Debut & More
@xconomy.com
4 years ago
ESMO 2019: PARP and Prostate, SeaGen’s Win, KRAS Update & More
@xconomy.com
4 years ago
Biotech Roundup: Vaping Toll Rises, NASH News, Akcea Shakeup & More
@xconomy.com
4 years ago
Bio Roundup: Sarepta’s Stumble, Opioid Suits, Shkreli’s Legacy & More
@xconomy.com
5 years ago
Bio Roundup: Bosley’s Editas Exit, Bridge Bucks, CRISPR Crime & More
@xconomy.com
5 years ago
Bio Roundup: #JPM19 Notes, Loxo Buyout, Black Diamond’s Cash & More
@xconomy.com
5 years ago
Bio Roundup: BIO Diversity, Allogene IPO, CRISPR In Utero & More